Effects of recombinant human growth hormone on enterocutaneous fistula patients

Table 1 General state of the patients

Age (Yr)	Sex	Weight (kg)	Distance from ligament of tretiz (cm)	Rest energy expenditure (KJ)	Enteral nutrition energy (KJ)
65	F	52	40	4276	6276
42	M	68	80	5648	8368
30	M	80	100	6192	9205
32	M	61	120	4384	6276
18	M	48	60	4322	6276
72	F	56	90	5773	8368
38	M	77	135	6158	9205
27	F	49	85	4359	6276

Table 2 Changes of intestinal mucosal villus height, PCNA and nitrogen excretion before and after treatment with rhGH

	The days when treated with rhGH
	0	4	7
Villus height (μm)	210.94 ± 49.16	500.54 ± 53.79b	459.03 ± 88.98b
PCNA labelling index (%)	12.92 ± 4.20	24.93 ± 3.41b	30.46 ± 5.24b
Nitrogen excretion (g/d)	7.25 ± 3.92	4.64 ± 1.95	3.40 ± 1.65a

All values are expressed as mean ± SD.

^aP < 0.05,

^bP < 0.01 vs day 0.

Table 3 Changes in body weight and serum proteins before and after treatment with rhGH

	The days when treated with rhGH
	0	4	7
Body weight (kg)	37.39 ± 12.48	38.64 ± 12.84	39.13 ± 12.19
Body mass index (kg/m2)	14.37 ± 3.28	15.21 ± 3.41	15.40 ± 3.24
Total proteins (g/L)	63.51 ± 2.47	70.52 ± 5.13b	74.89 ± 5.16b
Albumin (g/L)	35.74 ± 1.75	39.44 ± 1.18b	42.39 ± 1.68b
Prealbumin (mg/L)	180.88 ± 48.28	231.38 ± 52.31	286.38 ± 65.61a
Transferrin (g/L)	2.41 ± 0.14	2.49 ± 0.12	2.61 ± 0.12a
Fibronectin (mg/L)	172.5 ± 21.4	236.3 ± 16.5b	275.8 ± 16.9b

All values are expressed as mean ± SD.

^aP < 0.05,

^bP < 0.01 vs day 0.